참고문헌
- Abdul Rehman, Syed A., Kristariyanto Yosua, A., Choi, S.Y., Nkosi, P.J., Weidlich, S., Labib, K., Hofmann, K., and Kulathu, Y. (2016). MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes. Mol. Cell 63, 146-155. https://doi.org/10.1016/j.molcel.2016.05.009
- Bingol, B., Tea, J.S., Phu, L., Reichelt, M., Bakalarski, C.E., Song, Q., Foreman, O., Kirkpatrick, D.S., and Sheng, M. (2014). The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510, 370-375. https://doi.org/10.1038/nature13418
- Bondeson, D.P., Mares, A., Smith, I.E.D., Ko, E., Campos, S., Miah, A.H., Mulholland, K.E., Routly, N., Buckley, D.L., Gustafson, J.L., et al. (2015). Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611-U120. https://doi.org/10.1038/nchembio.1858
- Boselli, M., Lee, B.H., Robert, J., Prado, M.A., Min, S.W., Cheng, C., Silva, M.C., Seong, C., Elsasser, S., Hatle, K.M., et al. (2017). An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons. J. Biol. Chem. 292, 19209-19225. https://doi.org/10.1074/jbc.M117.815126
- Buckley, D.L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J.L., Smith, I.E., Miah, A.H., Harling, J.D., and Crews, C.M. (2015). HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem. Biol. 10, 1831-1837. https://doi.org/10.1021/acschembio.5b00442
- Buhimschi, A.D., Armstrong, H.A., Toure, M., Jaime-Figueroa, S., Chen, T.L., Lehman, A.M., Woyach, J.A., Johnson, A.J., Byrd, J.C., and Crews, C.M. (2018). Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Biochemistry-Us 57, 3564-3575. https://doi.org/10.1021/acs.biochem.8b00391
- Burslem, G.M., Smith, B.E., Lai, A.C., Jaime-Figueroa, S., McQuaid, D.C., Bondeson, D.P., Toure, M., Dong, H.Q., Qian, Y.M., Wang, J., et al. (2018). The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell Chemical Biology 25, 67-77. https://doi.org/10.1016/j.chembiol.2017.09.009
- Chan, A.I., McGregor, L.M., and Liu, D.R. (2015). Novel selection methods for DNA-encoded chemical libraries. Curr. Opin. Chem. Biol. 26, 55-61. https://doi.org/10.1016/j.cbpa.2015.02.010
- Chan, C.H., Morrow, J.K., Li, C.F., Gao, Y., Jin, G., Moten, A., Stagg, L.J., Ladbury, J.E., Cai, Z., Xu, D., et al. (2013). Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154, 556-568. https://doi.org/10.1016/j.cell.2013.06.048
- Chauhan, D., Tian, Z., Nicholson, B., Kumar, K.G., Zhou, B., Carrasco, R., McDermott, J.L., Leach, C.A., Fulcinniti, M., Kodrasov, M.P., et al. (2012). A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22, 345-358. https://doi.org/10.1016/j.ccr.2012.08.007
- Chen, J., Dexheimer, T.S., Ai, Y., Liang, Q., Villamil, M.A., Inglese, J., Maloney, D.J., Jadhav, A., Simeonov, A. and Zhuang, Z. (2011). Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem. Biol. 18, 1390-1400. https://doi.org/10.1016/j.chembiol.2011.08.014
- Chu, T.T., Gao, N., Li, Q.Q., Chen, P.G., Yang, X.F., Chen, Y.X., Zhao, Y.F., and Li, Y.M. (2016). Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation. Cell Chem. Biol. 23, 453-461. https://doi.org/10.1016/j.chembiol.2016.02.016
- Ciechanover, A. (2005). Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 6, 79-87. https://doi.org/10.1038/nrm1552
- Clague, M.J., Barsukov, I., Coulson, J.M., Liu, H., Rigden, D.J., and Urbe, S. (2013). Deubiquitylases from genes to organism. Physiol. Rev. 93, 1289-1315. https://doi.org/10.1152/physrev.00002.2013
- Coleman, K.G., and Crews, C.M. (2018). Proteolysis-Targeting Chimeras: Harnessing the Ubiquitin-Proteasome System to Induce Degradation of Specific Target Proteins. Annual Review of Cancer Biology 2, 41-58. https://doi.org/10.1146/annurev-cancerbio-030617-050430
- Colland, F., Formstecher, E., Jacq, X., Reverdy, C., Planquette, C., Conrath, S., Trouplin, V., Bianchi, J., Aushev, V.N., Camonis, J., et al. (2009). Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 8, 2286-2295. https://doi.org/10.1158/1535-7163.MCT-09-0097
- Crew, A.P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y.V., Hamman, B.D., Morgan, A., Ferraro, C., et al. (2018). Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. J. Med. Chem. 61, 583-598. https://doi.org/10.1021/acs.jmedchem.7b00635
- D'Arcy, P., Brnjic, S., Olofsson, M.H., Fryknas, M., Lindsten, K., De Cesare, M., Perego, P., Sadeghi, B., Hassan, M., Larsson, R., et al. (2011). Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 17, 1636-1640. https://doi.org/10.1038/nm.2536
- de Poot, S.A.H., Tian, G., and Finley, D. (2017). Meddling with Fate: The Proteasomal Deubiquitinating Enzymes. J. Mol. Biol. 429, 3525-3545. https://doi.org/10.1016/j.jmb.2017.09.015
- Deshaies, R.J., and Joazeiro, C.A. (2009). RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399-434. https://doi.org/10.1146/annurev.biochem.78.101807.093809
- Dexheimer, T.S., Rosenthal, A.S., Luci, D.K., Liang, Q., Villamil, M.A., Chen, J., Sun, H., Kerns, E.H., Simeonov, A., Jadhav, A., et al. (2014). Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer. J. Med. Chem. 57, 8099-8110. https://doi.org/10.1021/jm5010495
- Farshi, P., Deshmukh, R.R., Nwankwo, J.O., Arkwright, R.T., Cvek, B., Liu, J., and Dou, Q.P. (2015). Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opin. Ther. Pat. 25, 1191-1208. https://doi.org/10.1517/13543776.2015.1056737
- Finley, D. (2009). Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome. Annual Review of Biochemistry 78, 477-513. https://doi.org/10.1146/annurev.biochem.78.081507.101607
- Finley, D., and Chau, V. (1991). Ubiquitination. Annu. Rev. Cell. Biol. 7, 25-69. https://doi.org/10.1146/annurev.cb.07.110191.000325
- Fraile, J.M., Quesada, V., Rodriguez, D., Freije, J.M., and Lopez-Otin, C. (2012). Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 31, 2373-2388. https://doi.org/10.1038/onc.2011.443
- Gavory, G., O'Dowd, C.R., Helm, M.D., Flasz, J., Arkoudis, E., Dossang, A., Hughes, C., Cassidy, E., McClelland, K., Odrzywol, E., et al. (2018). Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat. Chem. Biol. 14, 118-125. https://doi.org/10.1038/nchembio.2528
- Gopinath, P., Ohayon, S., Nawatha, M., and Brik, A. (2016). Chemical and semisynthetic approaches to study and target deubiquitinases. Chem. Soc. Rev. 45, 4171-4198. https://doi.org/10.1039/C6CS00083E
- Gustafson, J.L., Neklesa, T.K., Cox, C.S., Roth, A.G., Buckley, D.L., Tae, H.S., Sundberg, T.B., Stagg, D.B., Hines, J., McDonnell, D.P., et al. (2015). Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. Angew. Chem. Int. Ed. Engl. 54, 9659-9662. https://doi.org/10.1002/anie.201503720
- Harrigan, J.A., Jacq, X., Martin, N.M., and Jackson, S.P. (2018). Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat. Rev. Drug Discov. 17, 57-77.
- Henning, R.K., Varghese, J.O., Das, S., Nag, A., Tang, G., Tang, K., Sutherland, A.M., and Heath, J.R. (2016). Degradation of Akt using protein-catalyzed capture agents. J. Pept. Sci. 22, 196-200. https://doi.org/10.1002/psc.2858
- Hines, J., Gough, J.D., Corson, T.W., and Crews, C.M. (2013). Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs. P. Natl. Acad. Sci. USA 110, 8942-8947. https://doi.org/10.1073/pnas.1217206110
- Huang, X., and Dixit, V.M. (2016). Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 26, 484-498. https://doi.org/10.1038/cr.2016.31
- Itoh, Y., Ishikawa, M., Naito, M., and Hashimoto, Y. (2010). Protein Knockdown Using Methyl Bestatin-Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins. J. Am. Chem. Soc. 132, 5820-5826. https://doi.org/10.1021/ja100691p
- Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M., and Hashimoto, Y. (2011). Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorg. Med. Chem. 19, 6768-6778. https://doi.org/10.1016/j.bmc.2011.09.041
- Jiang, Y., Deng, Q., Zhao, H., Xie, M., Chen, L., Yin, F., Qin, X., Zheng, W., Zhao, Y., and Li, Z. (2018). Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor alpha. ACS Chem. Biol. 13, 628-635. https://doi.org/10.1021/acschembio.7b00985
- Kapuria, V., Peterson, L.F., Fang, D., Bornmann, W.G., Talpaz, M., and Donato, N.J. (2010). Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis. Cancer Res. 70, 9265-9276. https://doi.org/10.1158/0008-5472.CAN-10-1530
- Kategaya, L., Di Lello, P., Rouge, L., Pastor, R., Clark, K.R., Drummond, J., Kleinheinz, T., Lin, E., Upton, J.P., Prakash, S., et al. (2017). USP7 small-molecule inhibitors interfere with ubiquitin binding. Nature 550, 534-538. https://doi.org/10.1038/nature24006
- Kluge, A.F., Lagu, B.R., Maiti, P., Jaleel, M., Webb, M., Malhotra, J., Mallat, A., Srinivas, P.A., and Thompson, J.E. (2018). Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorg. Med. Chem. Letters 28, 2655-2659. https://doi.org/10.1016/j.bmcl.2018.05.013
- Komander, D., Clague, M.J., and Urbe, S. (2009). Breaking the chains: structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 10, 550-563. https://doi.org/10.1038/nrm2731
- Komander, D., and Rape, M. (2012). The ubiquitin code. Annu. Rev. Biochem. 81, 203-229. https://doi.org/10.1146/annurev-biochem-060310-170328
- Lai, A.C., and Crews, C.M. (2017). Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101-114. https://doi.org/10.1038/nrd.2016.211
- Lai, A.C., Toure, M., Hellerschmied, D., Salami, J., Jaime-Figueroa, S., Ko, E., Hines, J., and Crews, C.M. (2016). Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew. Chem. Int. Ed. Engl. 55, 807-810. https://doi.org/10.1002/anie.201507634
- Lamberto, I., Liu, X., Seo, H.S., Schauer, N.J., Iacob, R.E., Hu, W., Das, D., Mikhailova, T., Weisberg, E.L., Engen, J.R., et al. (2017). Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. Cell Chem. Biol. 24, 1490-1500 e1411. https://doi.org/10.1016/j.chembiol.2017.09.003
- Lee, B.H., Lee, M.J., Park, S., Oh, D.C., Elsasser, S., Chen, P.C., Gartner, C., Dimova, N., Hanna, J., Gygi, S.P., et al. (2010). Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-U163. https://doi.org/10.1038/nature09299
- Lee, B.H., Lu, Y., Prado, M.A., Shi, Y., Tian, G., Sun, S., Elsasser, S., Gygi, S.P., King, R.W., and Finley, D. (2016). USP14 deubiquitinates proteasome-bound substrates that are ubiquitinated at multiple sites. Nature 532, 398-401. https://doi.org/10.1038/nature17433
- Li, J., Yakushi, T., Parlati, F., Mackinnon, A.L., Perez, C., Ma, Y., Carter, K.P., Colayco, S., Magnuson, G., Brown, B., et al. (2017). Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nat. Chem. Biol. 13, 486-493. https://doi.org/10.1038/nchembio.2326
- Liang, J.R., Martinez, A., Lane, J.D., Mayor, U., Clague, M.J., and Urbe, S. (2015). USP30 deubiquitylates mitochondrial Parkin substrates and restricts apoptotic cell death. Embo. Rep. 16, 618-627. https://doi.org/10.15252/embr.201439820
- Liu, N., Liu, C., Li, X., Liao, S., Song, W., Yang, C., Zhao, C., Huang, H., Guan, L., Zhang, P., et al. (2014a). A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Sci. Rep. 4, 5240.
- Liu, N.N., Li, X.F., Huang, H.B., Zhao, C., Liao, S.Y., Yang, C.S., Liu, S.T., Song, W.B., Lu, X.Y., Lan, X.Y., et al. (2014b). Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget 5, 5453-5471.
- Liu, Y.C., Lashuel, H.A., Choi, S., Xing, X.C., Case, A., Ni, J., Yeh, L.A., Cuny, G.D., Stein, R.L., and Lansbury, P.T. (2003). Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10, 837-846. https://doi.org/10.1016/j.chembiol.2003.08.010
- Long, M.J., Gollapalli, D.R., and Hedstrom, L. (2012). Inhibitor mediated protein degradation. Chem. Biol. 19, 629-637. https://doi.org/10.1016/j.chembiol.2012.04.008
- Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., and Jiang, Z. (2018). Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway. Eur. J. Med. Chem.146, 251-259. https://doi.org/10.1016/j.ejmech.2018.01.063
- Manasanch, E.E., and Orlowski, R.Z. (2017). Proteasome inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 14, 417. https://doi.org/10.1038/nrclinonc.2016.206
- Mistry, H., Hsieh, G., Buhrlage, S.J., Huang, M., Park, E., Cuny, G.D., Galinsky, I., Stone, R.M., Gray, N.S., D'Andrea, A.D., et al. (2013). Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol. Cancer Ther. 12, 2651-2662. https://doi.org/10.1158/1535-7163.MCT-13-0103-T
- Neklesa, T.K., Tae, H.S., Schneekloth, A.R., Stulberg, M.J., Corson, T.W., Sundberg, T.B., Raina, K., Holley, S.A., and Crews, C.M. (2011). Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nat. Chem. Biol. 7, 538-543. https://doi.org/10.1038/nchembio.597
- Neklesa, T.K., Winkler, J.D., and Crews, C.M. (2017). Targeted protein degradation by PROTACs. Pharmacol. Ther. 174, 138-144. https://doi.org/10.1016/j.pharmthera.2017.02.027
- Ohoka, N., Nagai, K., Hattori, T., Okuhira, K., Shibata, N., Cho, N., and Naito, M. (2014). Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway. Cell Death Dis. 5.
- Popovic, D., Vucic, D., and Dikic, I. (2014). Ubiquitination in disease pathogenesis and treatment. Nat. Med. 20, 1242-1253. https://doi.org/10.1038/nm.3739
- Raina, K., Lu, J., Qian, Y.M., Altieri, M., Gordon, D., Rossi, A.M.K., Wang, J., Chen, X., Dong, H.Q., Siu, K., et al. (2016). PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. P. Natl. Acad. Sci. USA 113, 7124-7129. https://doi.org/10.1073/pnas.1521738113
- Rask-Andersen, M., Almen, M.S., and Schioth, H.B. (2011). Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579-590. https://doi.org/10.1038/nrd3478
- Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., Harpon, J., Battaglia, V., Vivat, V., Sippl, W., et al. (2012). Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem. Biol. 19, 467-477. https://doi.org/10.1016/j.chembiol.2012.02.007
- Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498. https://doi.org/10.1056/NEJMoa043445
- Robb, C.M., Contreras, J.I., Kour, S., Taylor, M.A., Abid, M., Sonawane, Y.A., Zahid, M., Murry, D.J., Natarajan, A., and Rana, S. (2017). Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem. Commun. (Camb.) 53, 7577-7580. https://doi.org/10.1039/C7CC03879H
- Rodriguez-Gonzalez, A., Cyrus, K., Salcius, M., Kim, K., Crews, C.M., Deshaies, R.J., and Sakamoto, K.M. (2008). Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 27, 7201-7211. https://doi.org/10.1038/onc.2008.320
- Ross, C.A., and Poirier, M.A. (2004). Protein aggregation and neurodegenerative disease. Nat. Med. 10 Suppl, S10-17. https://doi.org/10.1038/nm1066
- Sacco, J.J., Coulson, J.M., Clague, M.J., and Urbe, S. (2010). Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life 62, 140-157.
- Sakamoto, K.M., Kim, K.B., Kumagai, A., Mercurio, F., Crews, C.M., and Deshaies, R.J. (2001). Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. P. Natl. Acad. Sci. USA 98, 8554-8559. https://doi.org/10.1073/pnas.141230798
- Salami, J., and Crews, C.M. (2017). Waste disposal-An attractive strategy for cancer therapy. Science 355, 1163-1167. https://doi.org/10.1126/science.aam7340
- Schiedel, M., Herp, D., Hammelmann, S., Swyter, S., Lehotzky, A., Robaa, D., Olah, J., Ovadi, J., Sippl, W., and Jung, M. (2018). Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals). J. Med. Chem. 61, 482-491. https://doi.org/10.1021/acs.jmedchem.6b01872
- Schneekloth, A.R., Pucheault, M., Tae, H.S., and Crews, C.M. (2008). Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorg. Med. Chem. Lett. 18, 5904-5908. https://doi.org/10.1016/j.bmcl.2008.07.114
- Schneekloth, J.S., Jr., Fonseca, F.N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., and Crews, C.M. (2004). Chemical genetic control of protein levels: selective in vivo targeted degradation. J. Am. Chem. Soc. 126, 3748-3754. https://doi.org/10.1021/ja039025z
- Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R.S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. USA 105, 3933-3938. https://doi.org/10.1073/pnas.0708917105
- Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Masszi, T., Spicka, I., Oriol, A., Hajek, R., Rosinol, L., Siegel, D.S., Mihaylov, G.G., et al. (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372, 142-152. https://doi.org/10.1056/NEJMoa1411321
- Tian, X., Isamiddinova, N.S., Peroutka, R.J., Goldenberg, S.J., Mattern, M.R., Nicholson, B., and Leach, C. (2011). Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format. Assay. Drug Dev. Technol. 9, 165-173. https://doi.org/10.1089/adt.2010.0317
- Tomoshige, S., Naito, M., Hashimoto, Y., and Ishikawa, M. (2015). Degradation of HaloTag-fused nuclear proteins using bestatin-HaloTag ligand hybrid molecules. Org. Biomol. Chem. 13, 9746-9750. https://doi.org/10.1039/C5OB01395J
- Turnbull, A.P., Ioannidis, S., Krajewski, W.W., Pinto-Fernandez, A., Heride, C., Martin, A.C.L., Tonkin, L.M., Townsend, E.C., Buker, S.M., Lancia, D.R., et al. (2017). Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature 550, 481-486. https://doi.org/10.1038/nature24451
- Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004). In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. 303, 844-848. https://doi.org/10.1126/science.1092472
- Wang, X., D'Arcy, P., Caulfield, T.R., Paulus, A., Chitta, K., Mohanty, C., Gullbo, J., Chanan-Khan, A., and Linder, S. (2015). Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem. Biol. Drug Des. 86, 1036-1048. https://doi.org/10.1111/cbdd.12571
- Wang, X., Feng, S., Fan, J., Li, X., Wen, Q., and Luo, N. (2016a). New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation. Biochem. Pharmacol. 116, 200-209. https://doi.org/10.1016/j.bcp.2016.07.017
- Wang, X., Mazurkiewicz, M., Hillert, E.K., Olofsson, M.H., Pierrou, S., Hillertz, P., Gullbo, J., Selvaraju, K., Paulus, A., Akhtar, S., et al. (2016b). The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci Rep-Uk 6, 26979. https://doi.org/10.1038/srep26979
- Weathington, N.M., and Mallampalli, R.K. (2014). Emerging therapies targeting the ubiquitin proteasome system in cancer. J. Clin. Invest. 124, 6-12. https://doi.org/10.1172/JCI71602
- Weinstock, J., Wu, J., Cao, P., Kingsbury, W.D., McDermott, J.L., Kodrasov, M.P., McKelvey, D.M., Suresh Kumar, K.G., Goldenberg, S.J., Mattern, M.R., et al. (2012). Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47. ACS Med. Chem. Lett. 3, 789-792. https://doi.org/10.1021/ml200276j
- Wilkinson, K.D. (1997). Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J. 11, 1245-1256. https://doi.org/10.1096/fasebj.11.14.9409543
- Winter, G.E., Buckley, D.L., Paulk, J., Roberts, J.M., Souza, A., DhePaganon, S., and Bradner, J.E. (2015). Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381. https://doi.org/10.1126/science.aab1433
- Xie, T., Lim, S.M., Westover, K.D., Dodge, M.E., Ercan, D., Ficarro, S.B., Udayakumar, D., Gurbani, D., Tae, H.S., Riddle, S.M., et al. (2014). Pharmacological targeting of the pseudokinase Her3. Nat. Chem. Biol. 10, 1006-1012. https://doi.org/10.1038/nchembio.1658
- Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.T., Leisten, E.D., and Tang, W. (2018). Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. Bioorg. Med. Chem. Lett. 28, 2493-2497. https://doi.org/10.1016/j.bmcl.2018.05.057
- Yue, W., Chen, Z., Liu, H., Yan, C., Chen, M., Feng, D., Yan, C., Wu, H., Du, L., Wang, Y., et al. (2014). A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30. Cell Res. 24, 482-496. https://doi.org/10.1038/cr.2014.20
- Zengerle, M., Chan, K.H., and Ciulli, A. (2015). Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. Acs. Chem. Biol. 10, 1770-1777. https://doi.org/10.1021/acschembio.5b00216
- Zhang, C., Han, X.R., Yang, X., Jiang, B., Liu, J., Xiong, Y., and Jin, J. (2018). Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). Eur. J. Med. Chem. 151, 304-314. https://doi.org/10.1016/j.ejmech.2018.03.071
- Zhou, B., Hu, J., Xu, F., Chen, Z., Bai, L., Fernandez-Salas, E., Lin, M., Liu, L., Yang, C.Y., Zhao, Y., et al. (2018). Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J. Med. Chem. 61, 462-481. https://doi.org/10.1021/acs.jmedchem.6b01816
- Zhou, P. (2005). Targeted protein degradation. Curr. Opin. Chem. Biol. 9, 51-55. https://doi.org/10.1016/j.cbpa.2004.10.012
피인용 문헌
- The Role of Ubiquitination in Regulating Embryonic Stem Cell Maintenance and Cancer Development vol.20, pp.11, 2019, https://doi.org/10.3390/ijms20112667
- PROTACs: great opportunities for academia and industry vol.4, pp.1, 2018, https://doi.org/10.1038/s41392-019-0101-6
- Significance of Selective Protein Degradation in the Development of Novel Targeted Drugs and Its Implications in Cancer Therapy vol.3, pp.6, 2018, https://doi.org/10.1002/adtp.201900210
- Deubiquitination Reactions on the Proteasome for Proteasome Versatility vol.21, pp.15, 2018, https://doi.org/10.3390/ijms21155312
- Ectopic expression of 35 kDa and knocking down of 78 kDa SG2NAs induce cytoskeletal reorganization, alter membrane sialylation, and modulate the markers of EMT vol.476, pp.2, 2018, https://doi.org/10.1007/s11010-020-03932-2
- Traceless Staudinger ligation enabled parallel synthesis of proteolysis targeting chimera linker variants vol.57, pp.8, 2018, https://doi.org/10.1039/d0cc05395c
- The Ubiquitin Proteasome System in Genome Stability and Cancer vol.13, pp.9, 2018, https://doi.org/10.3390/cancers13092235
- Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges vol.10, pp.12, 2018, https://doi.org/10.3390/cells10123309